Japan at a glance
- Population
- 123.4 million 2025
- Life expectancy at birth
- 84.0 years, 2024
- People aged 65 and over
- 30.0 % of people, 2025
- Health spending per person
- 3,638 US$ per person, 2023
- Doctors
- 2.65 per 1,000 people, 2022
Updated
Reviewed by Chandani Patel
Japan Multi-Cancer Early Detection Market Industry Trends and Forecast to 2034: Segmented by (Technology, Setting, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$766.6 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $88.4 Mn | — | — |
| 2025 (base) | $111.3 Mn | +$22.8 Mn | — |
| 2026 (forecast) | $140.0 Mn | +$28.7 Mn | +25.8% |
| 2027 (forecast) | $176.1 Mn | +$36.1 Mn | +58.3% |
| 2028 (forecast) | $221.5 Mn | +$45.4 Mn | +99.1% |
| 2029 (forecast) | $278.6 Mn | +$57.1 Mn | +150.5% |
| 2030 (forecast) | $350.5 Mn | +$71.9 Mn | +215.1% |
| 2031 (forecast) | $441.0 Mn | +$90.4 Mn | +296.4% |
| 2032 (forecast) | $554.7 Mn | +$113.8 Mn | +398.6% |
| 2033 (forecast) | $697.8 Mn | +$143.1 Mn | +527.3% |
| 2034 (forecast) | $877.9 Mn | +$180.0 Mn | +689.1% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $111.3 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $877.9 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 25.8% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Technology, setting and end user (see all) |
| Key players | GRAIL, Exact Sciences Corporation, Guardant Health, Inc., Freenome, Delfi Diagnostics (see all) |
| Regulator in Japan | PMDASource: Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Multi-cancer early detection tests look for signs of many cancer types in one blood draw, before symptoms appear.
Key segments of the multi-Cancer Early Detection market include technology (Methylation Analysis, Fragmentomics and Protein Biomarkers) and setting (Primary Care, Employer Programs and Direct-to-Consumer).
Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the multi-Cancer Early Detection market. Faster approvals and new combinations are improving survival.
Biomarker-led treatment, earlier lines of therapy and expansion into emerging markets offer strong growth for the multi-Cancer Early Detection market.
High treatment costs, drug resistance, side effects and unequal access to cancer centres hold back the multi-Cancer Early Detection market, especially in low- and middle-income countries.
The multi-Cancer Early Detection market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Medical devices are notified, certified or approved depending on their risk; the Pharmaceuticals and Medical Devices Agency (PMDA) reviews higher-risk devices for approval by the Ministry of Health, Labour and Welfare.[1] Everyone is covered by public health insurance, and the Ministry of Health, Labour and Welfare sets the official price list for covered medicines (NHI prices).[2]
[1] Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.
[2] Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how multi-Cancer Early Detection products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in Japan.
What doctors and scientists are doing in Multi-Cancer Early Detection right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 18 Nov 2026.
[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 18 Nov 2026.
[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 18 Nov 2026.
From our blog
Japan · 1 shared keyword
Japan
Japan
Japan
Japan
Japan
Digital Health · Japan
Healthcare Services · Japan
Pharmaceuticals · Japan
Pharmaceuticals · Japan
Healthcare Services · Japan
Pharmaceuticals · Japan